文献速递垂体与肾上腺疾病

垂体柄增厚的肿瘤性病因与自然病程

Neoplastic Etiology and Natural Course of Pituitary Stalk Thickening.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该系统评价纳入18项研究、共1368例垂体柄增厚(PST)患者,汇总分析显示肿瘤性病因占比为45.2%(95%CI,33.3%-57.8%),以生殖细胞肿瘤(14.0%)、朗格汉斯细胞组织细胞增生症(10.2%)和转移瘤(4.7%)最常见;儿童人群及至少一种垂体激素缺乏者比例超过50%的研究中,肿瘤占比更高。初始性质未明的病例随访中18.5%(95%CI,7.6%-38.3%)出现PST进展,提示随访影像学至关重要。

要点

  • PST患者中肿瘤性病因汇总占比为45.2%,儿童人群更高。
  • 生殖细胞肿瘤、朗格汉斯细胞组织细胞增生症与转移瘤为常见肿瘤病因。
  • 初始性质未明者随访中约18.5%出现PST进展,应重视随访影像。

核心结论

  • 垂体柄增厚常最终证实为肿瘤性病因,尤其在儿童人群中;孤立性PST常会进展,初始性质未明者需随访影像学。

研究设计与样本

  • 系统检索MEDLINE/PubMed与EMBASE数据库至2021年2月,纳入18项原始研究、共1368例PST患者,并对肿瘤性病因比例进行荟萃分析。

主要发现

  • 肿瘤性病因汇总比例为45.2%(95%CI,33.3%-57.8%),研究间异质性显著(I2=93%)。
  • 最常见肿瘤为生殖细胞肿瘤(占研究人群14.0%),其次为朗格汉斯细胞组织细胞增生症(10.2%)和转移瘤(4.7%)。
  • 儿童人群研究及至少一种垂体激素缺乏者超过50%的研究中肿瘤比例倾向更高。
  • 肿瘤组垂体柄更厚,但差异不显著(汇总均数差2.08 mm;P=.08)。
  • 初始性质未明病例中18.5%(95%CI,7.6%-38.3%)在随访中出现PST进展。

关键数值与推荐

  • 肿瘤性病因汇总比例45.2%(95%CI,33.3%-57.8%)。
  • 生殖细胞肿瘤占研究人群14.0%,朗格汉斯细胞组织细胞增生症占10.2%,转移瘤占4.7%。
  • 肿瘤与非肿瘤垂体柄厚度汇总均数差2.08 mm,P=.08。
  • 初始性质未明病例PST进展比例18.5%(95%CI,7.6%-38.3%)。

临床怎么用

  • 对PST患者应评估肿瘤性病因,儿童人群需重点排查。
  • 初始性质未明者应安排随访影像学以监测PST进展。
  • 垂体柄厚度差异不显著,不宜仅凭厚度区分肿瘤与非肿瘤。

局限性

  • 研究间异质性显著(I2=93%)。
  • 仅基于观察性研究的荟萃分析,随访进展数据来自初始性质未明病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Pituitary stalk thickening (PST) is often identified on magnetic resonance imaging (MRI), either incidentally or during diagnostic workup of hypopituitarism. However, the neoplastic etiology and natural course of PST are not fully understood, although this knowledge is required to establish diagnostic and surveillance strategies. OBJECTIVE: This work aimed to investigate the neoplastic etiology and natural course of PST. METHODS: MEDLINE/PubMed and EMBASE databases were searched up to February 2021 to identify original research investigating the etiologies of PST. The proportion of neoplastic etiology in patients with PST was meta-analytically pooled. Supplementary analysis exploring factors suggesting neoplasm was also performed. For initially indeterminate cases without confirmed diagnosis, the proportion of patients showing progression of PST during follow-up was evaluated. RESULTS: Eighteen studies covering 1368 patients with PST were included. The pooled proportion of neoplasm was 45.2% (95% CI, 33.3%-57.8%), with substantial heterogeneity across studies (I2 = 93%). The most common neoplasm was germ cell tumor (14.0% of study population), followed by Langerhans cell histiocytosis (10.2%) and metastasis (4.7%). The studies on pediatric populations and those with more than 50% of patients having at least one pituitary hormone deficiency tended to show a higher proportion of neoplasm. The pituitary stalk was thicker in neoplasms, but the difference was not significant (pooled mean difference, 2.08 mm; P = .08). In initially indeterminate cases, 18.5% (95% CI, 7.6%-38.3%) showed progression of PST during follow-up. CONCLUSION: PST was commonly confirmed to be neoplastic, especially in pediatric populations. As isolated PST frequently progresses, follow-up imaging is essential in initially indeterminate cases.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kim DY, Kim PH, Jung AY, et al. Neoplastic Etiology and Natural Course of Pituitary Stalk Thickening. J Clin Endocrinol Metab. 2022. PMID: 34614160. doi:10.1210/clinem/dgab732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。